Latest & greatest articles for menopause

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on menopause or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on menopause and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for menopause

121. Alternatives to HRT for the Management of Symptoms of the Menopause

Alternatives to HRT for the Management of Symptoms of the Menopause Alternatives to HRT for the Management of Symptoms of the Menopause Scientific Impact Paper No. 6 September 2010Alternatives to HRT for the Management of Symptoms of the Menopause This is the second edition of this Opinion Paper, which was originally published in 2006. 1. Background Despite recent encouraging data regarding the safety of traditional hormone replacement therapy (HRT), women and their primary care practitioners (...) of the publication from four years ago, aims to provide the reader with state-of-the-art knowledge on alternatives to HRT for the management of menopausal symptoms. 2. Lifestyle measures There is some evidence that women who are more active tend to suffer less from the symptoms of the menopause. 1 However, evidence from randomised controlled trials concerning the effects of aerobic exercise on vasomotor and other menopausal symptoms is limited. 2 The evidence suggests that aerobic exercise can improve

Royal College of Obstetricians and Gynaecologists2010

122. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society

Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society Menopause: The Journal of The North American Menopause Society Vol. 17, No. 1, pp. 23/24 DOI: 10.1097/gme.0b013e3181cdd4a7 * 2010 by The North American Menopause Society 5 Text printed on acid-free paper NAMS continuing medical education activity Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society This position (...) statement, which begins on page 25, has been designatedacontinuingmedicaleducation(CME)activityfrom The North AmericanMenopause Society(NAMS). GOAL To demonstrate an increase in, or affirmation of, current knowledge regarding the management of osteoporosis in postmenopausal women. LEARNING OBJECTIVES After reading this position statement, participants should be able to: & Describe the effect of menopause and aging on bone health. & Identify risk factors that contribute to fracture risk. & Discuss

The North American Menopause Society2010

123. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause

Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause 19468079 2009 06 25 2009 07 16 2016 10 19 1476-6256 170 1 2009 Jul 01 American journal of epidemiology Am. J. Epidemiol. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. 12-23 10.1093/aje/kwp115 The authors further analyzed results from the Women's Health Initiative randomized trials (1993-2004) of conjugated equine estrogens, with or without (...) medroxyprogesterone acetate, focusing on health benefits versus risks among women who initiated hormone therapy soon after menopause. Data from the Women's Health Initiative observational study (1993-2004) were included in some analyses for additional precision. Results are presented here for incident coronary heart disease, stroke, venous thromboembolism, breast cancer, colorectal cancer, endometrial cancer, or hip fracture; death from other causes; a summary global index; total cancer; and total mortality

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro

124. Urogenital health. In: Menopause and osteoporosis update 2009.

Urogenital health. In: Menopause and osteoporosis update 2009. Urogenital health. In: Menopause and osteoporosis update 2009. | National Guideline Clearinghouse Search Sign In Username or Email * Password * Remember Me Don't have an account? Guideline Summary NGC:006973 This guideline summary has been withdrawn from NGC. Please update your bookmarks. View all withdrawn summaries in the . About NGC Guideline Summaries NGC's guidelines summaries contain information systematically derived from

Society of Obstetricians and Gynaecologists of Canada2009

125. Hormone therapy and breast cancer. In: Menopause and osteoporosis update 2009.

Hormone therapy and breast cancer. In: Menopause and osteoporosis update 2009. Hormone therapy and breast cancer. In: Menopause and osteoporosis update 2009. | National Guideline Clearinghouse Search Sign In Username or Email * Password * Remember Me Don't have an account? Guideline Summary NGC:006972 This guideline summary has been withdrawn from NGC. Please update your bookmarks. View all withdrawn summaries in the . About NGC Guideline Summaries NGC's guidelines summaries contain information

Society of Obstetricians and Gynaecologists of Canada2009

126. Cardiovascular disease. In: Menopause and osteoporosis update 2009.

Cardiovascular disease. In: Menopause and osteoporosis update 2009. Cardiovascular disease. In: Menopause and osteoporosis update 2009. | National Guideline Clearinghouse Search Sign In Username or Email * Password * Remember Me Don't have an account? Guideline Summary NGC:006971 This guideline summary has been withdrawn from NGC. Please update your bookmarks. View all withdrawn summaries in the . About NGC Guideline Summaries NGC's guidelines summaries contain information systematically

Society of Obstetricians and Gynaecologists of Canada2009

127. Vasomotor symptoms. In: Menopause and osteoporosis update 2009.

Vasomotor symptoms. In: Menopause and osteoporosis update 2009. Vasomotor symptoms. In: Menopause and osteoporosis update 2009. | National Guideline Clearinghouse Search Sign In Username or Email * Password * Remember Me Don't have an account? Guideline Summary NGC:006970 This guideline summary has been withdrawn from NGC. Please update your bookmarks. View all withdrawn summaries in the . About NGC Guideline Summaries NGC's guidelines summaries contain information systematically derived from

Society of Obstetricians and Gynaecologists of Canada2009

129. Bone health. In: Menopause and osteoporosis update 2009.

Bone health. In: Menopause and osteoporosis update 2009. Bone health. In: Menopause and osteoporosis update 2009. | National Guideline Clearinghouse Search Sign In Username or Email * Password * Remember Me Don't have an account? Guideline Summary NGC:006975 This guideline summary has been withdrawn from NGC. Please update your bookmarks. View all withdrawn summaries in the . About NGC Guideline Summaries NGC's guidelines summaries contain information systematically derived from original

Society of Obstetricians and Gynaecologists of Canada2009

130. Mood, memory, and cognition. In: Menopause and osteoporosis update 2009.

Mood, memory, and cognition. In: Menopause and osteoporosis update 2009. Mood, memory, and cognition. In: Menopause and osteoporosis update 2009. | National Guideline Clearinghouse Search Sign In Username or Email * Password * Remember Me Don't have an account? Guideline Summary NGC:006974 This guideline summary has been withdrawn from NGC. Please update your bookmarks. View all withdrawn summaries in the . About NGC Guideline Summaries NGC's guidelines summaries contain information

Society of Obstetricians and Gynaecologists of Canada2009

131. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety

Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety 19167693 2009 03 03 2009 04 06 2015 11 19 1097-6868 200 3 2009 Mar American journal of obstetrics and gynecology Am. J. Obstet. Gynecol. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. 238.e1-238.e10 10.1016/j.ajog.2008.10.057 (...) The objective of the study was to assess the efficacy and safety of desvenlafaxine (administered as desvenlafaxine succinate) for the treatment of vasomotor symptoms. This was a 26 week, double-blind, placebo-controlled trial of 567 postmenopausal women (mean age, 53.7 years; time since natural menopause, 4.8 years) experiencing 50 or more hot flushes (HFs) per week, randomly assigned to desvenlafaxine (100 or 150 mg) or placebo. Change from baseline in average daily number of moderate to severe HFs

EvidenceUpdates2009

133. NIH State-of-the-Science Conference Statement on management of menopause-related symptoms.

NIH State-of-the-Science Conference Statement on management of menopause-related symptoms. NIH State-of-the-Science Conference Statement on management of menopause-related symptoms. | National Guideline Clearinghouse Search Sign In Username or Email * Password * Remember Me Don't have an account? Guideline Summary NGC:006071 This guideline summary has been withdrawn from NGC. Please update your bookmarks. View all withdrawn summaries in the . About NGC Guideline Summaries NGC's guidelines

National Institutes of Health (NIH) State-of-the-Science Panel2009

135. Hormone therapy for endometriosis and surgical menopause.

Hormone therapy for endometriosis and surgical menopause. BACKGROUND: Endometriosis is characterized by the presence of ectopic endometrial tissue that might lead to many distressing and debilitating symptoms. Despite available studies supporting standard hormone therapy for women with endometriosis and post-surgical menopause, there is still a concern that estrogens may induce a recurrence of the disease and its symptoms. OBJECTIVES: This review aimed to look at pain and disease recurrence (...) in women with endometriosis who used hormone therapy for post-surgical menopause. SEARCH STRATEGY: We searched the Cochrane Menstrual Disorders and Subfertility Group Specialized Register (March 2008), Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2008, Issue 3), MEDLINE (1966 to March 2008), EMBASE (1980 to March 2008), and references lists of articles. Relevant journals and conference proceedings were handsearched. SELECTION CRITERIA: Randomized controlled trials

Cochrane2009

136. Acupuncture for vasomotor menopausal symptoms: a systematic review

Acupuncture for vasomotor menopausal symptoms: a systematic review Acupuncture for vasomotor menopausal symptoms: a systematic review Acupuncture for vasomotor menopausal symptoms: a systematic review Cho SH, Whang WW CRD summary The review concluded that there was no consistent evidence that acupuncture was effective for treating menopausal vasomotor symptoms compared to sham acupuncture or hormone therapy; further research was warranted. The review was well conducted in most respects (...) and these cautious conclusions appear reliable. Authors' objectives To determine the effectiveness and tolerability of acupuncture for reducing menopausal vasomotor symptoms. Searching Nineteen electronic databases were searched to July 2008 (these included The Cochrane Library, MEDLINE, EMBASE, AMED, CINAHL, PsycINFO, Current Controlled Trials, NCCAM, www.library.nhs.uk/cam/, Japan Science and Technology Information Aggregator Electronic and several Korean and Chinese databases). Relevant journals

DARE.2009

137. Efficacy of isoflavones in relieving vasomotor menopausal symptoms: a systematic review

Efficacy of isoflavones in relieving vasomotor menopausal symptoms: a systematic review Efficacy of isoflavones in relieving vasomotor menopausal symptoms: a systematic review Efficacy of isoflavones in relieving vasomotor menopausal symptoms: a systematic review Jacobs A, Wegewitz U, Sommerfeld C, Grossklaus R, Lampen A CRD summary This review found no conclusive evidence that treatment with soy isoflavone supplementation improved vasomotor symptoms in perimenopausal and postmenopausal women (...) . Given the variation between studies and poor study quality, these cautious conclusions appear reasonable; however, there was some risk that relevant data were missed. Authors' objectives To investigate the efficacy of isoflavone supplements for the reduction of vasomotor symptoms in menopausal women. Searching Searches of 70 databases (from the German Institute of Medical Documentation and Information) were conducted to identify studies published in any language up to March 2008. Search terms were

DARE.2009

138. Cost effectiveness of exemestane versus tamoxifen in post-menopausal women with early breast cancer in Germany

Cost effectiveness of exemestane versus tamoxifen in post-menopausal women with early breast cancer in Germany Cost effectiveness of exemestane versus tamoxifen in post-menopausal women with early breast cancer in Germany Cost effectiveness of exemestane versus tamoxifen in post-menopausal women with early breast cancer in Germany Braun S, Mittendorf T, Menschik T, Greiner W, von der Schulenburg JM Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) were good, but there was a lack of information on the effectiveness data, which makes it unclear if the authors' conclusions are appropriate. Funding Not stated. Bibliographic details Braun S, Mittendorf T, Menschik T, Greiner W, von der Schulenburg JM. Cost effectiveness of exemestane versus tamoxifen in post-menopausal women with early breast cancer in Germany. Breast Care 2009; 4(6): 389-396 PubMedID DOI Original Paper URL Indexing Status Subject indexing assigned by CRD MeSH Androstadienes

NHS Economic Evaluation Database.2009

139. Cost-saving treatment strategies in in vitro fertilization: a combined economic evaluation of two large randomized clinical trials comparing highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone alpha

Cost-saving treatment strategies in in vitro fertilization: a combined economic evaluation of two large randomized clinical trials comparing highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone alpha Cost-saving treatment strategies in in vitro fertilization: a combined economic evaluation of two large randomized clinical trials comparing highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone alpha Cost-saving treatment (...) strategies in in vitro fertilization: a combined economic evaluation of two large randomized clinical trials comparing highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone alpha Wechowski J, Connolly M, Schneider D, McEwan P, Kennedy R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical

NHS Economic Evaluation Database.2009

140. Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK

Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK Lekander I, Borgstrom F, Strom O, Zethraeus N, Kanis JA Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of hormone replacement therapy (HRT) in women aged 50 years, who had menopausal symptoms, in comparison with no treatment. The authors concluded that HRT for women with menopausal symptoms was cost-effective. The methods were appropriate, but little information on the sources of the clinical and cost data was provided. The issue

NHS Economic Evaluation Database.2009